Browse the evidence

The Mediterranean diet is advised for cardiovascular prevention in patients with familial hypercholesterolemia (FH).

Practitioners should consider recommending the Mediterranean diet to patients with FH.

Limiting dietary fat and saturated fatty acids is an advised strategy for managing familial hypercholesterolemia.

Practitioners should advise FH patients to limit dietary fat and saturated fatty acids.

Supplementation of phytosterols and fiber can be helpful in managing familial hypercholesterolemia.

Practitioners may consider recommending phytosterol and fiber supplements to FH patients.

Patients on dialysis achieved a mean total body weight loss of 7.8% (SD 6.1) after being prescribed semaglutide.

Semaglutide may be an effective weight loss intervention for patients on dialysis.

Phase 2 trials of retatrutide report unprecedented weight reductions comparable to bariatric surgery.

Retatrutide may provide an effective alternative to surgical weight loss methods.

Weight loss was consistently larger in the incretin intervention groups than in placebo or lifestyle intervention comparators.

Incretin therapies may be more effective for weight loss compared to lifestyle changes or placebo.

Weight loss significantly explained heterogeneity in treatment effects on fibrosis improvement and MASH resolution.

Weight management should be emphasized in treatment plans for MASH to enhance treatment efficacy.

GLP-1 receptor agonist treatment is associated with a 10.3% reduction in fat mass (FM) at 6 months, 17.3% at 12 months, and 18.0% at 24 months.

GLP-1RA treatment leads to significant fat mass reduction over 24 months.

Clinical trials have demonstrated effectiveness in lowering HbA1c and body weight.

Evidence from clinical trials supports the use of Tirzepatide for improving glycemic control and reducing body weight.

Patients experienced an average weight loss of 16.06 ± 7.6 pounds at 12 weeks and 38.82 ± 11.4 pounds at 24 weeks.

Practitioners can expect significant weight loss in patients using compounded GLP-1 ± GIP agonists.

35% of protein supplement users take them for muscle mass increase.

Practitioners should emphasize muscle gain in discussions about protein supplementation.

The RESTART trial aims to evaluate whether a complex lifestyle intervention can improve and maintain cardiorespiratory fitness, muscle strength, and body composition among older adults with elevated cardiometabolic risk.

Practitioners can consider implementing complex lifestyle interventions to improve fitness and health in older adults at risk.

Secondary and tertiary outcomes include parameters such as muscle strength, physical activity levels, body composition, and health-related quality of life.

Practitioners should consider these additional outcomes when evaluating the impact of lifestyle interventions.

Weight decreases of 1.0% to 2.9%, 3.0% to 4.9%, and 5.0% or greater are associated with a lower risk of type 2 diabetes by 16%, 25%, and 26%, respectively.

Encouraging weight loss can significantly reduce the risk of developing type 2 diabetes.

Preventing weight gain and reducing weight are important for lowering the risk of type 2 diabetes in individuals with a BMI of 22 or greater.

Healthcare providers should focus on weight management strategies for individuals at risk of type 2 diabetes.

Superset training reduces session duration by approximately 50% compared to traditional resistance training.

Practitioners can recommend superset training as a time-efficient alternative to traditional resistance training.

63.4% of survivors of adolescent and young adult cancer had ≥5% weight reduction after anti-obesity medication initiation.

Practitioners may consider AOMs as a viable option for weight management in this population.

The proportion of survivors with severe obesity decreased from 60% to 35% after anti-obesity medication initiation.

AOMs may effectively reduce severe obesity in this demographic.

Anti-obesity medications are effective for weight reduction in survivors of adolescent and young adult cancer.

AOMs can be considered a treatment option for weight management in AYA cancer survivors.

Exogenous β-hydroxybutyrate (BHB) supplementation significantly reduced fat mass by 2 kg and improved body fat percentage in overweight and obese adults.

Practitioners may consider BHB supplementation as a strategy to enhance fat loss in overweight and obese clients.

Patients treated with GLP-1RAs achieved a mean absolute weight loss of 7.33 kg compared to baseline.

GLP-1RAs can be effective for weight loss in IBD patients.

GLP-1 receptor agonist type drugs can help patients achieve considerable weight loss.

Practitioners can consider GLP-1 RAs as a treatment option for weight loss in obese patients.

Nutritional deficiencies, particularly in vitamins and minerals, necessitate dietary counseling and supplementation for post-weight-loss patients.

Dietary counseling should be integrated into post-weight-loss care.

Liraglutide reduced total body mass and lowered absolute and percent android fat over 18 days.

Liraglutide may be effective for weight loss in individuals with type 2 diabetes.